Delivery Order HT942524D0009-HT942525F0013
Award Date
10/31/24
Potential Completion Date
12/30/24
Potential Value
$33K
Federal Agency
Defense Health Agency
Awardee
Leinco Technologies, Inc.
Ultimate Awardee
Not listed
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Fenton, MO, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $14,800 firm fixed-price purchase order was awarded on December 28, 2024 by the National Cancer Institute, a civilian agency, to Leinco Technologies, Inc., a self-certified small disadvantaged business manufacturer of goods. The contract is for laboratory testing services and has a period of performance through December 27, 2025. Leinco Technologies has previously served as a subcontractor to Battelle Memorial Institute, providing specialized antibodies and reagents for SARS-CoV-1 and...
This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $3,050,014.00 contract is for research, development, and production of mRNA vaccine antigens. This contract does not have a set-aside designation. Leidos Biomedical Research Inc. provides a broad range of research, development, and production services to...
This is a Cost Plus Fixed Fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for Good Manufacturing Practice (GMP) manufacturing of the LMB-2 immunotoxin, with a ceiling value of $1,021,037.00 and a performance period ending on September 24, 2025. The contract is not set aside for any specific socioeconomic category. Leidos Biomedical Research Inc. is an established Federally...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $27,474,922.00, was awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., for "Research, Development, Production and Support for Clinical Trials - Broadly Neutralizing Monoclonal Antibodies (BNMABs)." The contract does not have a set-aside...
This federal contract award, valued at $3,706,224, is a delivery order issued under prime contract 75N91019D00024 to Leidos Biomedical Research Inc. by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The delivery order is for COVID-19 related operational efforts. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. that provides a broad range of research, development, and production services to federal...
Leidos Biomedical Research Inc. was awarded a $19,358,814 delivery order contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to support human immunodeficiency virus (HIV) monoclonal antibody development. Specifically, the prime contractor will support cell line development, process development, analytical development, reagent production, manufacturing, and testing under the objectives of the prime award. The period of performance for these...
This is a $30,320,960.00 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the establishment of mRNA vaccine capability in support of NIAID's Vaccine Research Center (VRC) programs. The contract is a cost-plus-fixed-fee type with a period of performance through June 17, 2030. There is no set-aside...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., to facilitate the conduct of an observational study to characterize patients with COVID-19 infection (10,000 subjects). The contract has a ceiling value of $18,109,529.00 with a period of performance through January 31, 2027. It is a cost-plus-fixed-fee delivery order contract with no set-aside...
This federal contract award is for the "VRC RAPID MANUFACTURING RESPONSE: NCI FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACT" awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency. The $21,593,558.00 cost-plus-fixed-fee contract has an ultimate completion date of July 2, 2028 and was awarded on September 16, 2022 to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. Leidos Biomedical Research Inc. serves...
This federal contract award is for the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC). The prime contractor is Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. that provides comprehensive biomedical research and facilities support services to federal agencies, with a focus on the National Institutes of Health (NIH). The contract has an ultimate completion date of August 30, 2024, a ceiling value of $125,780,282.00, and is a...